Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results
Publication
, Conference
Reardon, DA; Quinn, J; Rich, J; Vredenburgh, J; Desjardins, A; Sathornsumetee, S; Salvado, A; Nikolova, Z; Bigner, D; Friedman, H
Published in: NEURO-ONCOLOGY
July 1, 2005
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
July 1, 2005
Volume
7
Issue
3
Start / End Page
291 / 291
Location
Edinburgh, SCOTLAND
Publisher
DUKE UNIV PRESS
Conference Name
2nd Quadrennial Meeting of the World-Federation-of-Neuro-Oncology/6th Meeting of the European-Association-for-Neur-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Quinn, J., Rich, J., Vredenburgh, J., Desjardins, A., Sathornsumetee, S., … Friedman, H. (2005). Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results. In NEURO-ONCOLOGY (Vol. 7, pp. 291–291). Edinburgh, SCOTLAND: DUKE UNIV PRESS.
Reardon, D. A., J. Quinn, J. Rich, J. Vredenburgh, A. Desjardins, S. Sathornsumetee, A. Salvado, Z. Nikolova, D. Bigner, and H. Friedman. “Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results.” In NEURO-ONCOLOGY, 7:291–291. DUKE UNIV PRESS, 2005.
Reardon DA, Quinn J, Rich J, Vredenburgh J, Desjardins A, Sathornsumetee S, et al. Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 291–291.
Reardon, D. A., et al. “Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results.” NEURO-ONCOLOGY, vol. 7, no. 3, DUKE UNIV PRESS, 2005, pp. 291–291.
Reardon DA, Quinn J, Rich J, Vredenburgh J, Desjardins A, Sathornsumetee S, Salvado A, Nikolova Z, Bigner D, Friedman H. Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results. NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 291–291.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
July 1, 2005
Volume
7
Issue
3
Start / End Page
291 / 291
Location
Edinburgh, SCOTLAND
Publisher
DUKE UNIV PRESS
Conference Name
2nd Quadrennial Meeting of the World-Federation-of-Neuro-Oncology/6th Meeting of the European-Association-for-Neur-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences